A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin ...

Emirates Health Services EHS takes centre stage at Arab Health 2025 medical expo showcasing a series of groundbreaking ...

Emirates Health Services (EHS) takes the spotlight at the Arab Health 2025 expo in Dubai, introducing pioneering projects ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

The study identified no safety issues, and the HIP-modified islet cells evaded immune responses. “These initial exciting results build upon the extensive preclinical and translational studies of ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

The Seattle-based biotech is evaluating UP421, a donor-derived allogeneic primary islet cell therapy, as a type 1 diabetes treatment that doesn’t require the use of any immunosuppression.

No safety issues were reported, and HIP-modified islet cells evaded immune responses without immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of ...